310 related articles for article (PubMed ID: 23426158)
1. Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters.
Armstrong AW; Parsi K; Schupp CW; Mease PJ; Duffin KC
JAMA Dermatol; 2013 May; 149(5):577-82. PubMed ID: 23426158
[TBL] [Abstract][Full Text] [Related]
2. Psoriasis and psoriatic arthritis video project: an update from the GRAPPA 2011 annual meeting.
Callis Duffin K; Armstrong AW; Mease PJ
J Rheumatol; 2012 Nov; 39(11):2198-200. PubMed ID: 23118287
[TBL] [Abstract][Full Text] [Related]
3. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort.
Walsh JA; McFadden M; Woodcock J; Clegg DO; Helliwell P; Dommasch E; Gelfand JM; Krueger GG; Duffin KC
J Am Acad Dermatol; 2013 Dec; 69(6):931-7. PubMed ID: 24054760
[TBL] [Abstract][Full Text] [Related]
4. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
[TBL] [Abstract][Full Text] [Related]
5. Using the Physician Global Assessment in a clinical setting to measure and track patient outcomes.
Pascoe VL; Enamandram M; Corey KC; Cheng CE; Javorsky EJ; Sung SM; Donahue KR; Kimball AB
JAMA Dermatol; 2015 Apr; 151(4):375-81. PubMed ID: 25549367
[TBL] [Abstract][Full Text] [Related]
6. Tele-assessment of Psoriasis Area and Severity Index: a study of the accuracy of digital image capture.
Singh P; Soyer HP; Wu J; Salmhofer W; Gilmore S
Australas J Dermatol; 2011 Nov; 52(4):259-63. PubMed ID: 22070699
[TBL] [Abstract][Full Text] [Related]
7. Psoriasis and psoriatic arthritis video project: an update from the 2012 GRAPPA annual meeting.
Callis Duffin K; Armstrong AW; Mease PJ
J Rheumatol; 2013 Aug; 40(8):1455-6. PubMed ID: 23908546
[TBL] [Abstract][Full Text] [Related]
8. Inter-observer reliability of the PASI in a clinical setting.
Cabrera S; Chinniah N; Lock N; Cains GD; Woods J
Australas J Dermatol; 2015 May; 56(2):100-2. PubMed ID: 25753553
[TBL] [Abstract][Full Text] [Related]
9. A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index.
Berth-Jones J; Thompson J; Papp K;
Br J Dermatol; 2008 Aug; 159(2):407-12. PubMed ID: 18565187
[TBL] [Abstract][Full Text] [Related]
10. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients.
Louden BA; Pearce DJ; Lang W; Feldman SR
Dermatol Online J; 2004 Oct; 10(2):7. PubMed ID: 15530297
[TBL] [Abstract][Full Text] [Related]
11. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased.
Jacobson CC; Kimball AB
Br J Dermatol; 2004 Aug; 151(2):381-7. PubMed ID: 15327545
[TBL] [Abstract][Full Text] [Related]
12. The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment.
Bożek A; Reich A
Adv Clin Exp Med; 2017 Aug; 26(5):851-856. PubMed ID: 29068583
[TBL] [Abstract][Full Text] [Related]
13. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment.
Berth-Jones J; Grotzinger K; Rainville C; Pham B; Huang J; Daly S; Herdman M; Firth P; Hotchkiss K
Br J Dermatol; 2006 Oct; 155(4):707-13. PubMed ID: 16965419
[TBL] [Abstract][Full Text] [Related]
14. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
15. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.
Robinson A; Kardos M; Kimball AB
J Am Acad Dermatol; 2012 Mar; 66(3):369-75. PubMed ID: 22041254
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2.
Duffin KC; Papp KA; Bagel J; Levi E; Chen R; Gottlieb AB
J Drugs Dermatol; 2017 Feb; 16(2):147-153. PubMed ID: 28300857
[TBL] [Abstract][Full Text] [Related]
17. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
18. Practice gaps. Inconsistency in clinical measurements can be improved through training: comment on "Standardizing training for psoriasis measures".
Swerlick RA
JAMA Dermatol; 2013 May; 149(5):582-3. PubMed ID: 23426397
[No Abstract] [Full Text] [Related]
19. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).
Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):452-6. PubMed ID: 24911993
[TBL] [Abstract][Full Text] [Related]
20. Artificial Intelligence-Based Psoriasis Severity Assessment: Real-world Study and Application.
Huang K; Wu X; Li Y; Lv C; Yan Y; Wu Z; Zhang M; Huang W; Jiang Z; Hu K; Li M; Su J; Zhu W; Li F; Chen M; Chen J; Li Y; Zeng M; Zhu J; Cao D; Huang X; Huang L; Hu X; Chen Z; Kang J; Yuan L; Huang C; Guo R; Navarini A; Kuang Y; Chen X; Zhao S
J Med Internet Res; 2023 Mar; 25():e44932. PubMed ID: 36927843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
